DEADLINE ALERT for OCGN, HMPT, TEDU, and ATHA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
July 09, 2021 11:35 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, July 09, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
July 02, 2021 17:42 ET
|
Ocugen
Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variantAdverse...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN
July 02, 2021 16:07 ET
|
The Rosen Law Firm PA
NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and...
DEADLINE ALERT for OCGN, HMPT, TEDU, and ATHA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
July 02, 2021 11:35 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, July 02, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN
June 21, 2021 17:46 ET
|
The Rosen Law Firm PA
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications
June 21, 2021 09:12 ET
|
Ocugen
MALVERN, Pa., June 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 18, 2021 16:12 ET
|
Ocugen
MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Set to Join Russell 3000® Index
June 16, 2021 07:30 ET
|
Ocugen
MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
June 15, 2021 07:30 ET
|
Ocugen
MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial
June 10, 2021 07:35 ET
|
Ocugen
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...